[go: up one dir, main page]

MX2009011822A - Hidroxi sulfonatos de compuestos de quinonicos y sus usos. - Google Patents

Hidroxi sulfonatos de compuestos de quinonicos y sus usos.

Info

Publication number
MX2009011822A
MX2009011822A MX2009011822A MX2009011822A MX2009011822A MX 2009011822 A MX2009011822 A MX 2009011822A MX 2009011822 A MX2009011822 A MX 2009011822A MX 2009011822 A MX2009011822 A MX 2009011822A MX 2009011822 A MX2009011822 A MX 2009011822A
Authority
MX
Mexico
Prior art keywords
quinone compounds
hydroxy sulfonate
sulfonate
hydroxy
quinone
Prior art date
Application number
MX2009011822A
Other languages
English (en)
Inventor
Manish Tandon
Judit Bartis
Erika Volckova
Deirdre Lowe
Marty Redmon
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of MX2009011822A publication Critical patent/MX2009011822A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona el 6-hidroxi-2, 2-dimetil-5-oxo3, 4, 5, 6-tetrahidro-2h-benzo (h) cromen-6-sulfonato de sodio y su síntesis y usos en el tratamiento del cáncer.
MX2009011822A 2007-04-30 2008-04-30 Hidroxi sulfonatos de compuestos de quinonicos y sus usos. MX2009011822A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91497107P 2007-04-30 2007-04-30
PCT/US2008/005656 WO2008134088A1 (en) 2007-04-30 2008-04-30 Hydroxy sulfonate of quinone compounds and their uses

Publications (1)

Publication Number Publication Date
MX2009011822A true MX2009011822A (es) 2010-01-14

Family

ID=39494644

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011822A MX2009011822A (es) 2007-04-30 2008-04-30 Hidroxi sulfonatos de compuestos de quinonicos y sus usos.

Country Status (13)

Country Link
US (1) US7790765B2 (es)
EP (1) EP2152686B1 (es)
JP (1) JP2010526072A (es)
KR (1) KR20100017483A (es)
CN (1) CN101687835B (es)
AU (1) AU2008246067B2 (es)
BR (1) BRPI0810717A2 (es)
CA (1) CA2685739C (es)
DK (1) DK2152686T3 (es)
ES (1) ES2532656T3 (es)
MX (1) MX2009011822A (es)
TW (1) TWI401081B (es)
WO (1) WO2008134088A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100209513A1 (en) * 2007-10-11 2010-08-19 In Geun Jo Pharmaceutical composition containing micronized particles of naphthoquinone-based compound
KR101405823B1 (ko) * 2007-12-24 2014-06-12 주식회사 케이티앤지생명과학 녹내장의 치료 및 예방을 위한 약제 조성물
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
JP6091431B2 (ja) 2011-01-31 2017-03-15 ルコラス−エム．ディー．リミテッド 医薬的使用
US9343930B2 (en) * 2012-05-25 2016-05-17 Baldor Electric Company Segmented stator assembly
CN106687344B (zh) * 2014-07-10 2019-07-09 罗伯特·博世有限公司 马达模组及abs液压单元
WO2016200934A1 (en) * 2015-06-08 2016-12-15 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Mitochondria-targeted lapachone compounds and uses therefor
US11090389B2 (en) 2016-10-13 2021-08-17 University of Pittsburgh—of the Commonwealth System of Higher Education Mitochondrially targeted PARP inhibitor, and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0040506B1 (en) 1980-05-21 1986-08-20 Teijin Limited Reactive polymer and process for the preparation thereof
US4963565A (en) * 1986-07-30 1990-10-16 National Jewish Center For Immunology And Respiratory Medicine In vivo treatment of mycobacterial infections with 6-cyclo octylamino-5,8-quinoline quinone
US5120843A (en) * 1987-04-27 1992-06-09 Upjohn Pharmaceutically active amines
FI102273B (fi) * 1989-09-11 1998-11-13 Eisai Co Ltd Kinonijohdannaiset, niiden valmistaminen ja niiden farmakologinen käyt tö
JP3111099B2 (ja) 1991-10-31 2000-11-20 科学技術振興事業団 水溶性高分子化薬剤の製造法
US5559156A (en) * 1993-09-30 1996-09-24 Glaxo Wellcome, Inc. Method for treating animals infected with Babesia spp.
WO1994004145A1 (en) 1992-08-21 1994-03-03 Dana Farber Cancer Institute Treatment of human viral infections
US5672607A (en) * 1993-01-29 1997-09-30 The United States Of America As Represented By The Department Of Health And Human Services Antiviral naphthoquinone compounds, compositions and uses thereof
GB2282384B8 (en) 1993-08-18 1997-09-04 Europ Economic Community Drug delivery agents incorporating mitomycin
EP0640609A1 (en) * 1993-08-24 1995-03-01 Ono Pharmaceutical Co., Ltd. Fused phenol derivatives having inhibitory activity on TXA2 synthetase, and 5-lipoxygenase and scavenging activity on oxygen species
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5763625A (en) 1995-04-25 1998-06-09 Wisconsin Alumni Research Foundation Synthesis and use of β-lapachone analogs
US5674900A (en) * 1995-06-06 1997-10-07 Shaman Pharmaceuticals, Inc. Terpenoid-type quinones for treatment of diabetes
US6245807B1 (en) * 1995-08-24 2001-06-12 Dana-Farber Cancer Institute Treatment of human prostate disease
US5824700A (en) * 1996-02-20 1998-10-20 Wisconsin Alumni Research Foundation Ortho-quinone derivatives novel synthesis therefor and their use in the inhibition of neoplastic cell growth
CN1304058C (zh) 1996-03-12 2007-03-14 Pg－Txl有限公司 水溶性紫杉醇产品
AU2411197A (en) 1996-04-30 1997-11-19 Affymax Technologies N.V. Methods for the synthesis of fmoc protected amines
JP2002541200A (ja) * 1999-04-14 2002-12-03 デイナ−ファーバー キャンサー インスティチュート，インコーポレイテッド 癌の処置のための方法および組成物
BR0010700A (pt) 1999-04-30 2002-02-13 Slil Biomedical Corp Conjugados análogos de poliamina e conjugados de quinona como terapias para cânceres e doenças na próstata
US6376470B1 (en) * 1999-09-23 2002-04-23 Enzon, Inc. Polymer conjugates of ara-C and ara-C derivatives
CN101507820A (zh) 1999-10-12 2009-08-19 细胞治疗公司 聚谷氨酸-治疗剂结合物的生产方法
CN1429121A (zh) 2000-03-17 2003-07-09 细胞治疗公司 聚谷氨酸－喜树碱结合物及其制备方法
EP1387677A2 (en) 2000-11-07 2004-02-11 Dana-Farber Cancer Institute, Inc. Method of treating hematologic tumors and cancers using beta lapachone
US6458974B1 (en) * 2001-01-25 2002-10-01 Cyclis Pharmaceuticals, Inc. Synthesis of β-lapachone and its intermediates
US6962944B2 (en) 2001-07-31 2005-11-08 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US7074824B2 (en) * 2001-07-31 2006-07-11 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
CZ293787B6 (cs) 2001-12-20 2004-07-14 Zentiva, A.S. pH senzitivní polymerní konjugáty antracyklinového kancerostatika pro cílenou terapii
AU2003228666A1 (en) 2002-04-23 2003-11-10 Case Western Reserve University Lapachone delivery systems, compositions and uses related thereto
US6608076B1 (en) * 2002-05-16 2003-08-19 Enzon, Inc. Camptothecin derivatives and polymeric conjugates thereof
WO2004006849A2 (en) 2002-07-15 2004-01-22 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
WO2004045557A2 (en) 2002-11-18 2004-06-03 Arqule, Inc. Novel lapachone compounds and methods of use thereof
JP2007523191A (ja) 2004-02-20 2007-08-16 アークル・インコーポレーテツド 血液腫瘍の治療のためのβ−ラパコンの使用
EP2033640A2 (en) 2004-02-20 2009-03-11 Arqule, Inc. Beta-lapachone for the treatment of lung cancer
US8614228B2 (en) * 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
WO2006020719A2 (en) * 2004-08-11 2006-02-23 Arqule, Inc. Aminoacid conjugates of beta - lapachone for tumor targeting
WO2006128120A2 (en) 2005-05-26 2006-11-30 Arqule, Inc. Novel lapachone compounds and methods of use thereof

Also Published As

Publication number Publication date
EP2152686A1 (en) 2010-02-17
CA2685739A1 (en) 2008-11-06
CN101687835B (zh) 2015-08-19
HK1139411A1 (en) 2010-09-17
BRPI0810717A2 (pt) 2016-05-24
EP2152686B1 (en) 2014-12-17
JP2010526072A (ja) 2010-07-29
AU2008246067B2 (en) 2011-10-20
DK2152686T3 (en) 2015-01-12
TW200913986A (en) 2009-04-01
TWI401081B (zh) 2013-07-11
CN101687835A (zh) 2010-03-31
US20090028952A1 (en) 2009-01-29
KR20100017483A (ko) 2010-02-16
WO2008134088A1 (en) 2008-11-06
ES2532656T3 (es) 2015-03-30
US7790765B2 (en) 2010-09-07
AU2008246067A1 (en) 2008-11-06
CA2685739C (en) 2016-06-14

Similar Documents

Publication Publication Date Title
IL258880A (en) Diarylhydantoin compounds
MX2009011822A (es) Hidroxi sulfonatos de compuestos de quinonicos y sus usos.
MY146112A (en) Long-term feed - cancer patient
MX2011014029A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida.
SG10201811480WA (en) Therapeutic compounds and compositions
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
MY159491A (en) Disubstituted phthalazine hedgehog pathway antagonists
MX2010003365A (es) Derivados de tiazol para el tratamiento de cancer.
MX2009012228A (es) Compuesto de triazolil aminopirimidina.
TNSN08400A1 (en) Organic compounds and their uses
TN2011000166A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
TW200727908A (en) Herbal composition for treating cancer
TW200716564A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
MX2009012233A (es) Compuestos de triazolil aminopirimidina.
UA93387C2 (ru) Производные пиримидина и их применение b качестве открывателей калиевых каналов kcnq
TW200605885A (en) Multicyclic lonidamine analogs
TW200738244A (en) 20-Alkyl, gemini vitamin D3 compounds and methods of use thereof
TW200716555A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
TW200714284A (en) Novel method
TW200613271A (en) Crystalline forms of 1,24(s)-dihydroxy vitamin d2
UA101379C2 (en) Amidophenoxyindazoles useful in the treatment of cancer
WO2006125139A3 (en) Therapeutic uses of kallikreins
UA91250C2 (en) 4-oxadiazolyl-piperidine compounds and use thereof
TW200716565A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration